JP2018516944A5 - - Google Patents

Download PDF

Info

Publication number
JP2018516944A5
JP2018516944A5 JP2017563314A JP2017563314A JP2018516944A5 JP 2018516944 A5 JP2018516944 A5 JP 2018516944A5 JP 2017563314 A JP2017563314 A JP 2017563314A JP 2017563314 A JP2017563314 A JP 2017563314A JP 2018516944 A5 JP2018516944 A5 JP 2018516944A5
Authority
JP
Japan
Prior art keywords
subject
motomeko
complement
gvhd
agent according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017563314A
Other languages
English (en)
Japanese (ja)
Other versions
JP6767396B2 (ja
JP2018516944A (ja
Filing date
Publication date
Priority claimed from GBGB1410116.6A external-priority patent/GB201410116D0/en
Application filed filed Critical
Priority claimed from PCT/EP2015/079172 external-priority patent/WO2016198133A1/en
Publication of JP2018516944A publication Critical patent/JP2018516944A/ja
Publication of JP2018516944A5 publication Critical patent/JP2018516944A5/ja
Application granted granted Critical
Publication of JP6767396B2 publication Critical patent/JP6767396B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017563314A 2014-06-06 2015-12-09 急性移植片対宿主病の治療に使用するためのオルニトドロス・モウバタ補体阻害剤 Expired - Fee Related JP6767396B2 (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB1410116.6A GB201410116D0 (en) 2014-06-06 2014-06-06 Method of treatment
PCT/EP2015/062742 WO2015185760A1 (en) 2014-06-06 2015-06-08 Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism
EPPCT/EP2015/062742 2015-06-08
PCT/EP2015/079172 WO2016198133A1 (en) 2015-06-08 2015-12-09 Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease

Publications (3)

Publication Number Publication Date
JP2018516944A JP2018516944A (ja) 2018-06-28
JP2018516944A5 true JP2018516944A5 (enExample) 2019-01-24
JP6767396B2 JP6767396B2 (ja) 2020-10-14

Family

ID=51266841

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016571246A Active JP7045133B2 (ja) 2014-06-06 2015-06-08 C5多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ(Ornithodoros moubata)補体阻害剤
JP2017563314A Expired - Fee Related JP6767396B2 (ja) 2014-06-06 2015-12-09 急性移植片対宿主病の治療に使用するためのオルニトドロス・モウバタ補体阻害剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016571246A Active JP7045133B2 (ja) 2014-06-06 2015-06-08 C5多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ(Ornithodoros moubata)補体阻害剤

Country Status (16)

Country Link
US (3) US11052129B2 (enExample)
EP (1) EP3151851B1 (enExample)
JP (2) JP7045133B2 (enExample)
KR (1) KR102439717B1 (enExample)
CN (1) CN106659767B (enExample)
AU (1) AU2015270396B2 (enExample)
BR (1) BR112016028446A2 (enExample)
CA (1) CA2951175A1 (enExample)
DK (2) DK3151851T3 (enExample)
ES (2) ES2906630T3 (enExample)
GB (1) GB201410116D0 (enExample)
IL (1) IL249237B (enExample)
MX (1) MX382757B (enExample)
PL (2) PL3151851T3 (enExample)
RU (1) RU2700932C2 (enExample)
WO (1) WO2015185760A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
CA2988313A1 (en) * 2015-06-08 2016-12-15 Volution Immuno Pharmaceuticals Sa Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease
GB201602802D0 (en) * 2016-02-17 2016-03-30 Volution Immuno Pharmaceuticals Sa Method of treatment
CN109328197A (zh) * 2016-06-07 2019-02-12 诺华股份有限公司 用于治疗具有补体c5多态性的患者的抗c5抗体
SE540754C2 (en) * 2016-11-30 2018-10-30 Ikea Supply Ag Molding of fiber blanks into three-dimensional fiber block
KR20190138650A (ko) * 2017-04-21 2019-12-13 볼루션 이뮤노 파마슈티컬스 에스에이 반흔성 안구 염증성 장애의 치료를 위한 코버신
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse
WO2019186084A1 (en) * 2018-03-26 2019-10-03 The University Of Liverpool Anti-complement histones
US20220047673A1 (en) * 2018-09-10 2022-02-17 Volution Immuno Pharmaceuticals Sa Coversin for Use in the Treatment of Rheumatic Diseases
GB201905810D0 (en) * 2019-04-25 2019-06-05 Volution Immuno Pharmaceuticals Sa Method of treatment
GB202218084D0 (en) 2022-12-01 2023-01-18 Volution Immuno Pharmaceuticals Sa Fusion proteins

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050054033A9 (en) * 1995-08-30 2005-03-10 Human Genome Sciences, Inc. Methods and compositions for treating and preventing infection using human interferon regulatory factor 3
GB0312619D0 (en) * 2003-06-02 2003-07-09 Evolutec Ltd Complement inhibitors
JP4772667B2 (ja) 2003-06-02 2011-09-14 エヴォルーテック・リミテッド 補体阻害剤
GB0518443D0 (en) * 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2061501B1 (en) 2006-09-08 2015-04-08 Volution Immuno Pharmaceuticals SA Method of treating respiratory disorders
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
GB0906779D0 (en) * 2009-04-20 2009-06-03 Natural Environment Res Council Composition
JP5840623B2 (ja) * 2010-01-08 2016-01-06 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 気道のウイルス感染症の治療に用いるev576
TW201418707A (zh) 2012-09-21 2014-05-16 Alexion Pharma Inc 補體組分c5拮抗劑之篩選分析
GB201410116D0 (en) * 2014-06-06 2014-07-23 Volution Immuno Pharmaceuticals Sa Method of treatment
DK3612208T5 (da) 2017-04-21 2024-09-02 Volution Immuno Pharmaceuticals Sa Coversin til behandlingen af autoimmune sygdomme med blisterdannelse

Similar Documents

Publication Publication Date Title
JP2018516944A5 (enExample)
Speer et al. Abnormal high-density lipoprotein induces endothelial dysfunction via activation of Toll-like receptor-2
Chamorro et al. The immunology of acute stroke
JP5759445B2 (ja) 病原体に対する哺乳類先天性免疫抵抗性の刺激のための組成物
Tabebordbar et al. Skeletal muscle degenerative diseases and strategies for therapeutic muscle repair
US20250221936A1 (en) Engineered hemichannels, engineered vesicles, and uses thereof
JP6992201B2 (ja) 合成ペプチド化合物及び使用方法
JP2017518316A5 (enExample)
JP2021523103A (ja) Il−33を含有するマトリックス結合型小胞(mbvs)およびそれらの使用
Sacks et al. Targeting complement at the time of transplantation
PE20130314A1 (es) PORCIONES DE ENLACE A ANTI-C5a CON ALTA ACTIVIDAD DE BLOQUEO
JP2016531910A5 (enExample)
JP2011528332A (ja) 哺乳動物ベータ・デフェンシンを用いた炎症性疾患の処置
ES2738287T3 (es) Inhibidor de la formación de trampas extracelulares en leucocitos
JP2015522264A5 (enExample)
WO2011149964A3 (en) Methods for treating or preventing vascular graft failure
JP2019533722A5 (enExample)
JPWO2019107530A5 (enExample)
Zhao et al. Synthetic oligodeoxynucleotides containing multiple telemeric TTAGGG motifs suppress inflammasome activity in macrophages subjected to oxygen and glucose deprivation and reduce ischemic brain injury in stroke-prone spontaneously hypertensive rats
JP2015510393A5 (enExample)
US20220048948A1 (en) Cd40 targeted peptides and uses thereof
JP2017522288A5 (enExample)
WO2016044493A1 (en) Compositions and methods for treating acute radiation syndrome
EA202190310A1 (ru) Белок для лечения воспалительных заболеваний
JP2019508175A5 (enExample)